K031055

### **ATTACHMENT 6**

# 510(k) Summary

JUL 0 7 2003

#### 1. Applicant's Name and Address

Straumann USA (on behalf of Institut Straumann AG)

Reservoir Place 1601 Trapelo Road Waltham, MA 02451

Telephone Number: 800-448-8168

781-890-0791

Fax Number:

Linda Jalbert

Contact Person:

Director, Regulatory Affairs

#### 2. Name of the Device

Trade Name:

ITI® DENTAL IMPLANT SYSTEM

Common Name:

Endosseous dental implants

Classification Name:

Endosseous dental implants

21 CFR 872.3640

#### 3. Legally Marketed Devices to which Equivalence is Claimed (Predicate Devices)

ITI Dental Implant System

Implant Innovations Inc. Osseotite Dental Implants(K013570)

#### 4. **Description of the Device**

ITI implants have an anchorage surface that is grit blasted then acid etched (SLA surface) or titanium plasma-sprayed (TPS surface). The implants are composed of Grade 4 titanium, cold worked. The neck of the implant, intended to remain above the crest of the bone on implantation, is a smooth machined surface to allow for the attachment of epithelial tissue. ITI implants are available in a range of endosseous diameters (3.3 to 4.8 mm) and lengths.

#### 5. Indications for Use

ITI implants are intended for surgical placement in the maxillary and/or mandibular arches to provide support for prosthetic restorations in edentulous or partially edentulous patients. The ITI Dental Implants are for single-stage or twostage surgical procedures.

# 6. Basis for Substantial Equivalence

The subject ITI® dental implants are identical in intended use to currently marketed ITI® dental implants. As with the predicate device, Implant Innovations Inc. Osseotite Dental Implants, the contraindication regarding tobacco use has been removed.

The subject ITI® implants are identical in all respects to previously cleared ITI implants. There has been no change in material, surface treatment, design, or operating principle.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JUL 0 7 2003

Ms. Linda Jalbert Director, Regulatory Affairs Straumann USA Reservoir Place 1601 Trapelo Road Waltham, Massachusetts 02451

Re: K031055

Trade/Device Name: ITI® Dental Implant System

Regulation Number: 21 CFR 872.3640 Regulation Name: Endosseous Implant

Regulatory Class: III Product Code: DZE Dated: April 2, 2003

Received: April 9, 2003

### Dear Ms. Jalbert:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4613. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Susan Runner, DDS, MA

Susen Punsin

Interim Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

# **ATTACHMENT 8**

## **Indications for Use Statement**

### **Device Name:**

ITI® Dental Implant System

## Indications for Use:

ITI implants are intended for surgical placement in the maxillary and/or mandibular arches to provide support for prosthetic restorations in edentulous or partially edentulous patients. The ITI Dental Implants are for single-stage or two-stage surgical procedures.

(Division Sign-Off)

Division of Anesthesiology, General Hospital,

Infection Control, Dental Devices

510(k) Number: K 031055